Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
66 search results for:

ACR/ARP 2019 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 24-02-2020 | Teaser

    ACR/ARP 2019

    Coverage from the 2019 ACR/ARP Annual Meeting. Includes research news and expert commentary on the NORDSTAR, RITAZAREM, and SELECT-AXIS 1 trials.

  2. 15-11-2019 | Teaser

    More expert interviews from ACR/ARP 2019

    Watch more interviews with researchers and independent experts on clinical trials presented at ACR/ARP 2019.

  3. 20-09-2019 | Image

    Back to the ACR/ARP 2019 conference hub
  4. 28-08-2019 | ACR/ARP 2019 | Channel

    ACR/ARP 2019

    ACR/ARP 2019- Atlanta, USA.

  5. 21-02-2019 | Spondyloarthropathies | Feature | Article
    Updated June 2022

    Trials of JAK inhibitors in spondyloarthritis: A round-up

    Related news story:  Upadacitinib shows promise for PsA SELECT-AXIS 1: Ankylosing spondylitis Phase 2/3 Patient population: Biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs Treatment groups: Upadacitinib 15 mg/day or placebo Status: Published https://clinicaltrials.gov/ct2/show/NCT03178487 The SELECT-AXIS 1 results were published in  The Lancet  and reported at the ACR/ARP Annual Meeting in Atlanta, Georgia, USA, in November 2019.

    Author:
    Claire Barnard
  6. 13-11-2019 | Axial spondyloarthritis | ACR/ARP 2019 | Article

    Secukinumab may represent a treatment option for nonradiographic axSpA

    The PREVENT investigators have reported positive results for the IL-17A inhibitor secukinumab in patients with nonradiographic axial spondyloarthritis at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10)
  7. 12-11-2019 | Vaccination | ACR/ARP 2019 | Article

    Study challenges safety concerns over live vaccine use in rheumatic disease patients

    Trial findings reported at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, refute concerns that patients with rheumatic diseases taking TNF inhibitors should not be given the live varicella virus vaccine.

    Published in:
    Arthritis Rheumatol  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  8. 11-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    TULIP-1 results fail to support phase II findings for anifrolumab in SLE

    The primary endpoint of the study, presented at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA and simultaneously published in The Lancet Rheumatology , was the proportion of patients achieving an SLE responder index (SRI)-4 response at 1 year.

    Published in:
    ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  9. 11-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Reassurance on MACE, VTE risk with upadacitinib

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  10. 19-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Omega-3 supplements may benefit in RA patients

    By Lucy Piper m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol.  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol.  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  11. 18-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    No benefit of add-on fenebrutinib for patients with SLE

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  12. 15-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    Further investigation of telitacicept may be warranted for SLE

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  13. 12-11-2019 | Ankylosing spondylitis | ACR/ARP 2019 | Article

    Upadacitinib demonstrates potential for ankylosing spondylitis

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Lancet 2019; doi:10.1016/S0140-6736(19)32534-6 Lancet 2019; doi:10.1016/S0140-6736(19)32681-9 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Lancet 2019; doi:10.1016/S0140-6736(19)32534-6 Lancet 2019; doi:10.1016/S0140-6736(19)32681-9 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  14. 12-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

    Guselkumab shows promise for PsA

    medwireNews : Findings from the DISCOVER-1 and DISCOVER-2 trials presented at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, suggest that the interleukin (IL)-23 inhibitor guselkumab may be a promising treatment option for people with psoriatic arthritis (PsA).

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  15. 13-11-2019 | Behçet’s disease | ACR/ARP 2019 | Article

    Apremilast reduces oral ulcer burden in Behçet’s syndrome

    By Laura Cowen m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology N Engl J Med 2019; 381 : 1918–1928 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  16. 13-11-2019 | Systemic lupus erythematosus | ACR/ARP 2019 | Article

    TULIP-2 meets primary endpoint for anifrolumab efficacy in SLE

    This phase III study, the second to be presented on the subject at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA, supports the secondary endpoint findings from TULIP-1, already reported by medwireNews .

    Published in:
    Arthritis Rheumatol  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  17. 13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Methotrexate plus glucocorticoids compare favorably with biologics in early RA

    By Lucy Piper m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  18. 13-11-2019 | Juvenile idiopathic arthritis | ACR/ARP 2019 | Article

    Tofacitinib shows efficacy in polyarticular juvenile idiopathic arthritis

    By Lucy Piper m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Arthritis Rheumatol.  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Arthritis Rheumatol.  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 Novembe
  19. 13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Olokizumab shows promise for moderate-to-severe RA

    The study findings were presented in a poster at the 2019 ACR/ARP Annual Meeting in Atlanta, Georgia, USA.

    Published in:
    Arthritis Rheumatol 2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  20. 11-11-2019 | Osteoarthritis | ACR/ARP 2019 | Article

    Short-term prednisolone offers HOPE for painful hand osteoarthritis

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group This information is brought to you by medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology Lancet 2019; doi:10.1016/S0140-6736(19)32489-4 Lancet 2019; doi:10.1016/S0140-6736(19)32729-1 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

    Published in:
    Lancet 2019; doi:10.1016/S0140-6736(19)32489-4 Lancet 2019; doi:10.1016/S0140-6736(19)32729-1 ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.